Who Paid My Doc
Wendi Tilson
Physician Assistant Wichita, KS Physician Assistant
NPI 1821067323 CMS profile 11002106
550 N Hillside St, Wichita, KS 67201
General payments
$2,728
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Wendi Tilson of Wichita, KS is reported in the CMS Open Payments database as having received $2,728 across 32 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 84th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,642 | 19 | |
| 2023 | General | $122 | 1 | |
| 2022 | General | $149 | 3 | |
| 2021 | General | $815 | 9 |
Beside peers
- Wendi Tilson
- Physician Assistant median
- Middle half of Physician Assistant
- National median
In program year 2025, general payments to Wendi Tilson were reported at $1,642. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.
Show as a table
| Year | Wendi Tilson | Physician Assistant median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $34 | $17–$122 | $163 |
| 2020 | $0 | $33 | $16–$78 | $114 |
| 2021 | $815 | $132 | $37–$438 | $132 |
| 2022 | $149 | $155 | $48–$522 | $149 |
| 2023 | $122 | $167 | $52–$557 | $160 |
| 2024 | $0 | $178 | $55–$600 | $164 |
| 2025 | $1,642 | $184 | $57–$620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
322
Drug cost
$9,547
Branded share of claims
8.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 12 | $7,022 | |
| Colchicine | Generic | 17 | $646 | |
| Oxycodone Hcl | Generic | 98 | $574 | |
| Amiodarone Hcl | Generic | 37 | $549 | |
| Gabapentin | Generic | 50 | $460 | |
| Potassium Chloride | Generic | 19 | $107 | |
| Metoprolol Tartrate | Generic | 33 | $59 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 16 | $53 | |
| Atorvastatin Calcium | Generic | 13 | $51 | |
| Furosemide | Generic | 27 | $25 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Records
32 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant in Kansas
Related records
Physician Assistant in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.